DK3590924T3 - Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf - Google Patents
Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf Download PDFInfo
- Publication number
- DK3590924T3 DK3590924T3 DK18761354.2T DK18761354T DK3590924T3 DK 3590924 T3 DK3590924 T3 DK 3590924T3 DK 18761354 T DK18761354 T DK 18761354T DK 3590924 T3 DK3590924 T3 DK 3590924T3
- Authority
- DK
- Denmark
- Prior art keywords
- unknown
- application
- pharmaceutical composition
- isoindolin
- derivative
- Prior art date
Links
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D209/49—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide and having in the molecule an acyl radical containing a saturated three-membered ring, e.g. chrysanthemumic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710112364 | 2017-02-28 | ||
| CN201710725987 | 2017-08-22 | ||
| PCT/CN2018/077324 WO2018157779A1 (zh) | 2017-02-28 | 2018-02-27 | 一种新的异二氢吲哚衍生物、其药物组合物及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3590924T3 true DK3590924T3 (da) | 2022-01-03 |
Family
ID=63369785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18761354.2T DK3590924T3 (da) | 2017-02-28 | 2018-02-27 | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11337964B2 (da) |
| EP (1) | EP3590924B1 (da) |
| JP (1) | JP6942380B2 (da) |
| KR (1) | KR102318401B1 (da) |
| CN (1) | CN110291065B (da) |
| AU (1) | AU2018228541B2 (da) |
| CA (1) | CA3052516C (da) |
| DK (1) | DK3590924T3 (da) |
| ES (1) | ES2902052T3 (da) |
| NZ (1) | NZ756231A (da) |
| PL (1) | PL3590924T3 (da) |
| RU (1) | RU2728829C1 (da) |
| WO (1) | WO2018157779A1 (da) |
| ZA (1) | ZA201905098B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109280027A (zh) * | 2018-12-13 | 2019-01-29 | 康化（上海）新药研发有限公司 | 一种5,6-二甲氧基-2-吡啶甲酸的合成方法 |
| CN111777518A (zh) * | 2019-04-03 | 2020-10-16 | 上海安谱实验科技股份有限公司 | 一种稳定同位素标记的苯乙醇胺a的合成制备方法 |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020246329A1 (ja) * | 2019-06-05 | 2020-12-10 | 住友化学株式会社 | β－ケトスルホン化合物の製造方法 |
| BR112022000965A2 (pt) | 2019-07-27 | 2022-06-14 | Brii Biosciences Inc | Derivado de adenosina e composição farmacêutica que compreende o mesmo |
| CN110423213B (zh) * | 2019-08-22 | 2021-06-04 | 上海英诺富成生物科技有限公司 | 一种阿普斯特衍生物及其制备方法与应用 |
| CN110627694B (zh) * | 2019-10-18 | 2021-06-15 | 山东邹平大展新材料有限公司 | 一种回收3-乙氧基-4-甲氧基-α-[(甲基磺酰基)甲基]-苯甲胺的方法 |
| CN112979442A (zh) * | 2019-12-12 | 2021-06-18 | 上海安谱实验科技股份有限公司 | 一种稳定同位素标记的甲基香兰素及其合成方法 |
| CN113121404B (zh) * | 2019-12-30 | 2024-07-09 | 江苏先声药业有限公司 | 阿普斯特的合成方法 |
| CN115397819A (zh) * | 2020-02-24 | 2022-11-25 | 苏州隆博泰药业有限公司 | Pde4抑制剂化合物及其医药用途 |
| CN113527179B (zh) * | 2020-04-13 | 2023-07-07 | 苏州璞正医药有限公司 | 链烃取代异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途 |
| CN112898132B (zh) * | 2020-10-23 | 2023-03-14 | 上海安谱实验科技股份有限公司 | 一种稳定同位素氘标记的甲基三氯生的合成方法 |
| CA3202049A1 (en) | 2021-01-25 | 2022-07-28 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| CN116801884B (zh) | 2021-01-25 | 2026-02-27 | 腾盛博药生物科技有限公司 | 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法 |
| CN114790164B (zh) * | 2021-08-13 | 2022-12-27 | 苏州璞正医药有限公司 | 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途 |
| EP4568945A1 (en) | 2022-08-11 | 2025-06-18 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Halophthalimide compounds and methods of use against tbi, inflammatory disorder, autoimmune disorder, neurodegenerative disease or viral infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006200033B8 (en) * | 1998-10-30 | 2008-09-11 | Celgene Corporation | Substituted phenethylsulfones and methods of reducing TNF-alpha levels |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| ZA200507284B (en) | 2003-03-12 | 2007-03-28 | Celgene Corp | 7-amino-isoindolyl compounds and their pharmaceutical uses |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| JP2008523102A (ja) * | 2004-12-13 | 2008-07-03 | セルジーン・コーポレーション | Ｐｄｅ４モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用 |
| PL2276483T3 (pl) * | 2008-03-27 | 2014-09-30 | Celgene Corp | Stałe postacie zawierające (+)-2-[1-(3-etoksy-4-metoksyfenylo)-2-metylosulfonyloetylo]-4-acetyloaminoizoindolino-1,3-dion, kompozycje je zawierające i ich zastosowania |
| MX361467B (es) | 2008-10-29 | 2018-12-06 | Celgene Corp | Compuestos de isoindolina para uso en el tratamiento de cancer. |
| US9045453B2 (en) | 2008-11-14 | 2015-06-02 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US8124646B2 (en) | 2009-06-18 | 2012-02-28 | Concert Pharmaceuticals, Inc. | Substituted isoindoline-1,3-dione derivatives |
| WO2012083153A1 (en) * | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
| MX347928B (es) * | 2011-01-10 | 2017-05-19 | Celgene Corp | Derivados de fenetilsulfona isoindolina y su uso. |
| WO2012097116A2 (en) | 2011-01-14 | 2012-07-19 | Celgene Corporation | Isotopologues of isoindole derivatives |
| EP2730278A1 (en) * | 2012-11-08 | 2014-05-14 | Ratiopharm GmbH | Composition melt |
| EP3142748B1 (en) * | 2014-05-15 | 2019-09-11 | Celgene Corporation | Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis |
| US20170087129A1 (en) * | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
-
2018
- 2018-02-27 DK DK18761354.2T patent/DK3590924T3/da active
- 2018-02-27 JP JP2019547071A patent/JP6942380B2/ja active Active
- 2018-02-27 EP EP18761354.2A patent/EP3590924B1/en active Active
- 2018-02-27 CA CA3052516A patent/CA3052516C/en active Active
- 2018-02-27 AU AU2018228541A patent/AU2018228541B2/en active Active
- 2018-02-27 PL PL18761354T patent/PL3590924T3/pl unknown
- 2018-02-27 WO PCT/CN2018/077324 patent/WO2018157779A1/zh not_active Ceased
- 2018-02-27 ES ES18761354T patent/ES2902052T3/es active Active
- 2018-02-27 NZ NZ756231A patent/NZ756231A/en unknown
- 2018-02-27 RU RU2019130390A patent/RU2728829C1/ru active
- 2018-02-27 US US16/488,794 patent/US11337964B2/en active Active
- 2018-02-27 CN CN201880011566.0A patent/CN110291065B/zh active Active
- 2018-02-27 KR KR1020197024513A patent/KR102318401B1/ko active Active
-
2019
- 2019-07-31 ZA ZA2019/05098A patent/ZA201905098B/en unknown
-
2022
- 2022-02-04 US US17/665,456 patent/US11628161B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220152002A1 (en) | 2022-05-19 |
| AU2018228541A1 (en) | 2019-09-05 |
| US11337964B2 (en) | 2022-05-24 |
| AU2018228541B2 (en) | 2020-07-16 |
| ZA201905098B (en) | 2020-12-23 |
| JP6942380B2 (ja) | 2021-09-29 |
| RU2728829C1 (ru) | 2020-07-31 |
| CA3052516A1 (en) | 2018-09-07 |
| US20200061033A1 (en) | 2020-02-27 |
| KR102318401B1 (ko) | 2021-10-29 |
| ES2902052T3 (es) | 2022-03-24 |
| PL3590924T3 (pl) | 2022-01-24 |
| WO2018157779A1 (zh) | 2018-09-07 |
| EP3590924A4 (en) | 2020-02-19 |
| EP3590924B1 (en) | 2021-10-27 |
| CN110291065A (zh) | 2019-09-27 |
| NZ756231A (en) | 2021-12-24 |
| US11628161B2 (en) | 2023-04-18 |
| EP3590924A1 (en) | 2020-01-08 |
| JP2020509017A (ja) | 2020-03-26 |
| KR20190122678A (ko) | 2019-10-30 |
| CA3052516C (en) | 2022-08-16 |
| CN110291065B (zh) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3590924T3 (da) | Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf | |
| DK3607069T3 (da) | Produkter og sammensætninger | |
| DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
| DK3442973T3 (da) | Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme | |
| EP3600325A4 (en) | UNIQUE COMPOSITIONS AND PROCESSES | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3580561T3 (da) | Hla-baserede metoder, sammensætninger og anvendelse heraf | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
| EP3845532A4 (en) | QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| EP3426348A4 (en) | 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| DK3214081T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3603620T3 (da) | Liposomsammensætning og farmaceutisk sammensætning | |
| PL3500255T3 (pl) | Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| DK3704227T3 (da) | Sammensætning og fremgangsmåde | |
| DK3494119T3 (da) | Forbindelser og sammensætninger og anvendelser deraf | |
| DK3399978T3 (da) | Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3409660T3 (da) | Cyklisk aminderivat og farmaceutisk anvendelse deraf | |
| DK3423076T3 (da) | Topisk cyclosporinholdige formuleringer og anvendelser deraf | |
| EP3436467A4 (en) | INNOVATIVE COMPOSITIONS AND THERAPEUTIC PROCEDURES | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder |